Association of adverse events (AES) with efficiacy outcomes for cabozantinib (C) in patients (PTS) with advanced hepatocellular carcinoma (AHCC) in the phase 3 celestial trial

Authors
Category Primary study
JournalOncology Research and Treatment
Year 2020
This article has no abstract
Epistemonikos ID: 5e4e1318cc737cfc9f4574b0e2eb35d272736cc1
First added on: Nov 24, 2025